Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May;53(9):1050.
doi: 10.1111/apt.16340.

Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply

Stanislas Pol  1 , Clovis Lusivika Nzinga  2 , Fabrice Carrat  3   4
Affiliations
Free article
Comment

Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply

Stanislas Pol et al. Aliment Pharmacol Ther. 2021 May.
Free article
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Pol S, ANRS, AFEF Study Group. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort. Aliment Pharmacol Ther. 2021;53:616-629.
    1. Wang J-G, Chen R, Wang L-C. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients. Aliment Pharmacol Ther. 2021;53:1048-1049.
    1. Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444-1453.
    1. Sung JJY, Tsoi KKF, Wong VWS, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28:1067-1077.
    1. Su F, Berry K, Ioannou GN. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut. 2020. gutjnl-2019-319867. https://doi.org/10.1136/gutjnl-2019-319867

MeSH terms